Fig. 2From: Synthesis, anticancer evaluation, molecular docking and ADME study of novel pyrido[4ʹ,3ʹ:3,4]pyrazolo[1,5-a]pyrimidines as potential tropomyosin receptor kinase A (TrKA) inhibitorsLarotrectinib and entrectinib as type-I multi-target kinase inhibitorsBack to article page